Federal Grant Award Summary

The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $604,902 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The award supports research titled "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy," which focuses on developing precision medicine approaches for a specific subtype of kidney cancer. The research will be conducted at the Institute's New York facilities and is expected to advance understanding of fumarate hydratase (FH)-deficient renal cell carcinoma and identify targeted therapeutic interventions to improve treatment outcomes.

Under this Military Medical Research and Development program award, Sloan-Kettering Institute will deliver research and development services including hypothesis-driven investigations, mechanistic studies, and therapeutic target identification aligned with the DHA's priorities to advance healthcare innovations. The award represents the Institute's continued participation in the program's competitive peer and programmatic review process, which emphasizes both technical merit and military relevance. The three-year performance period aligns with typical DHA funding timelines and supports the Institute's established expertise in precision oncology, genomic profiling, and translational cancer research conducted in partnership with affiliated academic medical centers.